WoundClot

WoundClot is an innovative startup focused on advanced bleeding control with its next-generation hemostatic gauze. The company's flagship product, WoundClot™ Hemostatic Gauze, is engineered to effectively manage mild, moderate, and severe bleeding. This bioabsorbable CE Class III Implantable device is designed for use during surgical procedures to manage capillary, venous, and arterial bleeding.

One of WoundClot's key differentiators is its rapid resorption profile, with the gauze being broken down and absorbed by the body in 7-14 days on average. Additionally, it is the world's only Non-Oxidized, Non-Regenerated Cellulosic Structure (NONRCS) Hemostatic, further setting it apart in the market. The company is committed to enhancing wound care through innovation and strategic partnerships, aiming to revolutionize patient recovery.

Founded in 2012 and based in Israel, WoundClot operates in the Health Care and Manufacturing industries. While specific details about the last investment and investors are currently unavailable, the company's pioneering technology and potential for disruption make it an intriguing prospect for venture capitalists seeking opportunities in the medical device and healthcare innovation space.